XORTX Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of XORTX Therapeutics generated cash of -$6,583,165, which is more than the previous year. Cash used in financing activities reached the amount of -$361,044 last year. Net change in cash is therefore -$6,986,531.
Cash Flow
| 2016 | -107.78K | -24.56K | 115K |
|---|---|---|---|
| 2017 | 91.17K | -12.48K | -33.52K |
| 2018 | -1.55M | -154.80K | 1.90M |
| 2019 | -249.58K | -7.03K | 55.21K |
| 2020 | -728.40K | -14.35K | 855.40K |
| 2021 | -4.75M | -31.22K | 19.18M |
| 2022 | -8.81M | -44.22K | 4.73M |
| 2023 | -6.58M | -46.36K | -361.04K |
XRTX.V Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 10.43M | 13.88M | 134.32K | 58.61K | 260.01K | 61.93K | 16.76K | 34.11K |
Operating activities | ||||||||
Net income | -2.15M | -6.98M | -1.29M | -1.28M | -629.57K | -3.77M | -474.20K | -414.83K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 105.17K | 55.45K | 14.02K | 20.43K | 19.9K | 19.31K | 16.77K | 16.02K |
Stock-based compensation expense | 120.98K | 487.94K | 396.42K | 230.12K | 26.31K | 0 | 92.67K | 203.87K |
| Deferred income tax benefit | 120.98K | 487.94K | 396.42K | 230.12K | 26.31K | 0 | 92.67K | 203.87K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 20 | -43.61K | -29.16K | -42.99K | 14.78K | -20.06K | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -6.58M | -8.81M | -4.75M | -728.40K | -249.58K | -1.55M | 91.17K | -107.78K |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -5 | -44.22K | -31.22K | -14.35K | -7.03K | -41.07K | -12.48K | -24.56K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | -280.95K | 0 | 0 |
Cash generated by investing activities | -46.36K | -44.22K | -31.22K | -14.35K | -7.03K | -154.80K | -12.48K | -24.56K |
Financing activities | ||||||||
Common Stock Issued | -299.73K | 4.99M | 17.88M | 900K | 70K | 1.95M | 33.7K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -66.08K | -20.41K | 0 | 0 | 0 | 0 | 79.52K | 0 |
Cash used in financing activities | -361.04K | 4.73M | 19.18M | 855.40K | 55.21K | 1.90M | -33.52K | 115K |
Net Change In Cash | -6.98M | -3.48M | 14.65M | 112.65K | -201.40K | 198.08K | 45.17K | -17.34K |
Cash at end of period | 3.44M | 10.40M | 14.78M | 171.27K | 58.61K | 260.01K | 61.93K | 16.76K |